Bispecific antibodies (bsAbs) represent a transformative force in modern medicine, offering innovative approaches to combat complex diseases. These specialized molecules are designed to simultaneously target two different antigens.
Bispecific drugs hold immense promise in revolutionizing therapeutic interventions across various medical fields. In this article, we explore three examples of bispecifics and their applications, illuminating their remarkable potential in advancing patient care. From hematologic malignancies to hemophilia treatment, we discover notable examples of bispecific drugs and their roles in transforming the treatment landscape.
Bispecific drugs have rapidly gained traction in therapeutic development, offering novel treatment modalities for a wide range of diseases. Here, we examine several notable examples of bispecific drugs and their applications in clinical practice.
Blinatumomab, a bispecific T cell engager (BiTE) antibody, is designed to target both CD19 on B cells and CD3 on T cells.1 This unique mechanism of action facilitates the direct engagement of cytotoxic T cells with malignant B cells, resulting in targeted cell lysis.
Subscribe to our Newsletter
Get all the latest updates, and learn about our advancements in antibody production.
Subscribe now
Blinatumomab has demonstrated efficacy in the treatment of acute lymphoblastic leukemia (ALL), particularly in patients with minimal residual disease (MRD). Its approval marked a significant milestone in the field of bsAb therapy and paved the way for the development of similar agents.
Catumaxomab is a trifunctional bsAb that targets epithelial cell adhesion molecule (EpCAM) on tumor cells and CD3 on T cells, while simultaneously engaging with Fcγ receptors on accessory immune cells.
This trifunctional approach enables the recruitment of various immune effector cells—including T cells, NK cells, and macrophages—to the tumor microenvironment, resulting in enhanced tumor cell killing.2 Catumaxomab has been approved for the treatment of malignant ascites in patients with EpCAM-positive carcinomas, offering a targeted therapeutic option for this challenging condition. (However, it has since been removed from market for commercial reasons.3)
Emicizumab is a bsAb designed to mimic the function of factor VIII and restore hemostasis in patients with hemophilia A.4 By simultaneously binding to activated factor IXa and factor X, Emicizumab facilitates the formation of the tenase complex, promoting effective clot formation. This innovative approach offers a prophylactic treatment option for patients with hemophilia A, reducing the frequency of bleeding episodes and improving overall quality of life. Emicizumab represents a paradigm shift in the management of hemophilia and has been widely adopted in this patient population.
We are proud to be part of advancing the field of bispecific drug development through our expertise in antibody production services. With a steadfast commitment to excellence and innovation, evitria offers comprehensive support to researchers and therapeutic companies, guiding them through the intricate process of bispecific antibody development.
Leveraging cutting-edge technologies and unparalleled expertise, we offer expression services for all common bispecific antibody formats. Whether it’s the Duobody system, innovative formats like IgG-scFvs, or other related formats, we possess the capabilities and know-how to deliver high-quality bispecific antibodies for therapeutic development. Furthermore, we guide you in finding the suitable bispecific antibody format.
Through collaboration with researchers and therapeutic companies, we contribute to the advancement of novel bispecific drug candidates, ultimately driving innovation and improving patient care.